Company / Cash & Equivalents
ELITE PHARMACEUTICALS INC /NV/ Cash & Equivalents History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$7.1M
FY2024
5-year range
$3.2M / $8.5M
FY2020-FY2024
Trend
-9.3%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $9M to $7M over the past 2 years.
Based on SEC 10-K filings.
$7M in FY2024 with a 5-year CAGR of +25.6%.
Declined from $9M to $7M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +30.6%
- 5-Year CAGR
- +25.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +25.6%, indicating consistent growth.
- In FY2024, cash & equivalents decreased 9.3% year-over-year.
- Peak cash & equivalents was recorded in FY2016.
- Lowest cash & equivalents in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.19 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $7.1M | -9.3% |
| FY2023 | $7.8M | -8.2% |
| FY2022 | $8.5M | +167.3% |
| FY2021 | $3.2M | +182.1% |
| FY2020 | $1.1M | -50.3% |
| FY2019 | $2.3M | -68.3% |
| FY2018 | $7.2M | -32.2% |
| FY2017 | $10.6M | -8.0% |
| FY2016 | $11.5M | +54.2% |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026